Circulating tumor DNA as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with advanced gastrointestinal stromal tumors

Last Updated: Wednesday, August 6, 2025

This phase II trial investigated circulating tumor DNA (ctDNA) as a biomarker in patients with advanced gastrointestinal stromal tumor who were treated with imatinib and binimetinib. Analysis of plasma and tumor tissue using genomic assays revealed a 39% baseline ctDNA detection rate, which was significantly higher in treatment-naïve patients. Active therapy negatively impacted ctDNA detection of primary and secondary KIT alterations. However, ctDNA responses sometimes preceded radiographic responses, suggesting potential for further investigation.

Clinical Cancer Research

Beta-elemene promotes ferroptosis to improve the sensitivity of imatinib in gastrointestinal stromal tumours by targeting N6AMT1

Phase 2 trial of ponatinib in patients with metastatic gastrointestinal stromal tumor following failure or intolerance of prior therapy with imatinib (POETIG trial)

Oncology Letters

Prolonged survival of a case with three different malignancies - cutaneous malignant melanoma, gastrointestinal stromal tumor and thyroid papillary cancer: A case report